We discuss the negative results of a randomized controlled trial of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers cessation in G4 or G5 stage chronic kidney disease. We next review the initiation modalities of dapagliflozine and finerenone in chronic kidney disease patients. Lastly, we review the recent therapeutic advances in IgA nephropathy treatment.
Key Words
Albuminuria, chronic kidney disease, IgA nephropathy, SGLT2-inhibitors, renin-angiotensin-system blockers, dapagliflozine, empagliflozine, finerenone, nefecon